New injection shows promise for Hard-to-Treat lymphoma
Disease control
Recruiting now
This early-stage study tests a new drug called KSV01 in 18 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check safety and find the right dose. Researchers will monitor side effects and look for signs that the…
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated May 14, 2026 12:03 UTC